Evaluation of BCL6 and MUM1 Expression in Patients with Diffuse Large B cell Lymphoma and their Correlations with Staging and Prognosis in Iran

  • Rahimi, Hossein (Hematology Oncology Department, Mashhad University of Medical Science) ;
  • Jafarian, Amirhossein (Pathology Department, Cancer and Molecular Pathology Research Center, Mashhad University of Medical Science) ;
  • Samadi, Alireza (Internal Medicine Research Center for Patient Safety, Mashhad University of Medical Science) ;
  • Meamar, Bahram (Pathology, Cancer Research Center, Mashhad University of Medical Science) ;
  • Rahmani, Shaghayegh (Research Center for Patient Safety, Mashhad University of Medical Science)
  • Published : 2015.02.04


Background: Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkins lymphoma (NHL), accounting for approximately 25% of NHL cases. The aim of this study was to evaluate the association between the BCL6 and MUM1 gene expression and patient prognosis and stage. Materials and Methods: After ethical approval, in a cross-sectional study, tissue samples of 80 patients with diffuse large B-cell lymphoma were analyzed for BCL6 and MUM1 gene expression. Immunohistochemical staining was performed with division into categories of 0-5%, 5-25%, 26-50%, 51-75% and more than 75%. Other clinical and histological information such as lymph node involvement, T-stage, B symptoms and patient outcome were also recorded. Data were analyzed with SPSS version 16 and a P-value less than 0.05 was considered significant. Results: The patient mean age was $46.9{\pm}10.5$ years ($47.6{\pm}10.7$ and $46.1{\pm}9.6$ for males and females, respectively). A significant association was seen between lymphoma stage and BCL6 (p=0.045) but not MUM1 expression (p=0.09). However, the latter was associated with mortality (p=0.006) as was also the BCL6 level (p=0.006). Conclusions: : Overexpression of MUM1 and BCL6 is associated with poor prognosis in patients with diffuse large B-cell lymphoma.


  1. Anderson J, Fordham S, Overman L, et al (2009). Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centrelike tumours displaying different survival characteristics. Int J Oncol, 35, 961-71.
  2. Bodoon K, Matalka I, Hayajneh R, Haddad Y, Gharaibeh W (2012). Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis. Asian Pac J Cancer Prev, 13, 3037-46.
  3. Colomo L, Lopez-Guillermo A, Perales M, et al (2003). Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 101, 78-84
  4. Cook NR (2007). Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation, 115, 928-35.
  5. Davies AJ, Rosenwald A, Wright G, et al (2007). Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol, 136, 286-93.
  6. De Mello CA, De Andrade VP, De Lima VC, Carvalho AL, Soares FA (2011). Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma. Leuk Lymphoma, 52, 1495-503.
  7. Gascoyne RD (2014). The biology of diffuse large B cell lymphoma (dlbcl). Pathology, 1, 32.
  8. Gatter KC, Warnke RA (2001). Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. WHO classification of tumors. pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; p. 171-4.
  9. Habara T, Sato Y, Takata K, et al (2012). Germinal center B-celllike versus non-germinal center B-cell-like as important prognostic factor for localized nodal DLBCL. J Clin Exp Hematop, 52, 91-9.
  10. Kolokotronis A, Konstantinou N, Christakis I, et al (2005). Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: a clinical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 99, 303-10.
  11. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M (2005). Epidemiology of non-Hodgkin's lymphoma (NHL): Trends, geographic distribution, and etiology. Ann Hematol, 84, 1-12
  12. Sehn LH, Donaldson J, Chhanabhai M (2005). Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 23, 5027-33.
  13. Vaque JP, Martinez N, Batlle-Lopez A (2014). B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica, 99, 222-31.
  14. Zhang Z, Shen Y, Shen D, Ni X (2012). Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma. BMC Gastroenterol, 25, 77.